Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Re-Pricing Rule for “Huge-Seller” Drugs Necessary Compromise to Protect Universal Healthcare While Promoting Innovation: Health Minister
January 12, 2016
- Kaketsuken Faces 110-Day Biz Suspension, Urged to Dissolve as Legal Entity
January 8, 2016
- Careful Administration Re-stressed for Inavir, Relenza in Dairy-Sensitive Patients: Safety Bulletin
January 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for December 2015
January 8, 2016
- Shipment of Some Lots of Kaketsuken’s Kenketsu Globulin OK’ed
January 7, 2016
- Health Policy Bureau’s FY2016 Draft Budget Earmarks 5.7 Billion Yen to Promote Clinical Research
January 5, 2016
- Health Service Bureau Increases Budgets for Measures against Hepatitis, Infectious Diseases: FY2016 Draft Budget
January 5, 2016
- Gist of FY2016 Drug Pricing Reform
December 25, 2015
- Chuikyo OKs Outline of FY2016 Drug Pricing Reform
December 25, 2015
- 130 Million Yen Earmarked to Boost PMDA Staffers for Accelerating Review: FY2016 Budget
December 25, 2015
- MHLW Looked at Innovativeness, Seriousness of Target Disease to Select Sakigake Products
December 25, 2015
- MHLW Launches Confab to Shore Up Healthcare Startup Sector
December 25, 2015
- Drug Price Cuts to Save 174.9 Billion Yen in State Coffers: MOF
December 25, 2015
- FY2016 Draft Budget Includes 82.5 Bil. Yen to Promote Creation of Innovative New Drugs and Medical Devices
December 25, 2015
- AMED-Led Screening Consortium Gets Underway with 22 Japanese Makers
December 24, 2015
- Plavix, 15 Other Brands to Lose Premiums on Generic, Biosimilar Entries; Re-Pricing Could Deal Another Blow
December 24, 2015
- MHLW OKs Add’l Indications for Remicade, Other Drugs
December 22, 2015
- Drug Prices to Be Pared 7.8% If Re-Pricing, Z2, Generic Price Cuts Included
December 22, 2015
- 3.6 Billion Yen in FY2015 Extra Budget to Go to IFN-Free Hep C Therapies
December 21, 2015
- Japan, India Sign Memorandum for Regulatory Affairs
December 21, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…